スタッフ紹介

学歴

2004年3月

北海道立札幌西高校　卒業

2011年3月

浜松医科大学医学部医学科　卒業

2019年3月

北海道大学院医学研究科医学専攻　博士課程　修了

職務経歴

2011年4月

北見赤十字病院　初期臨床研修医

2013年4月

北見赤十字病院　消化器内科　医員

2015年4月

市立稚内病院　内科　副医長

2016年4月

北海道大学 大学院医学研究院 消化器内科学教室　医員

2019年4月

厚生労働省 健康局 がん・疾病対策課　肝炎対策推進室・Ｂ型肝炎訴訟対策室　室長補佐

2021年4月

国立病院機構 北海道医療センター　消化器内科　医員

2022年4月

北海道大学病院　消化器内科　特任助教

2024年4月

肝疾患相談センター兼任

所属学会・資格

• 日本内科学会　認定内科医
• 日本消化器病学会　消化器病専門医　北海道支部評議員
• 日本肝臓学会　肝臓専門医　東部会評議員
• 日本消化器内視鏡学会
• 日本臨床腫瘍学会
• 日本再生医療学会
• 日本病態栄養学会
• JMECCインストラクター／ICLSインストラクター

受賞歴・研究助成歴

• 日本学術振興会　科学研究費助成事業
  若手研究「肝筋連関を介したサルコペニア及び肝線維化改善に係る因子の同定」研究代表者（R4年度-R6年度）
• 厚生労働科学研究費補助金　肝炎等克服政策研究事業
  「新たな手法を用いた肝炎ウイルス検査受検率・陽性者受診率の向上に資する研究」班（是永班）　研究分担者（R4年度）
  
  「肝炎ウイルス検査受検率の向上及び受診へ円滑につなげる方策の確立に資する研究」班（是永班）　研究分担者（R5年度～）
  
  「多様な病態に対応可能な肝疾患のトータルケアに資する人材育成及びその活動の質の向上等に関する研究」班（江口班）　研究分担者（R5年度～）

業績
（論文）

1. Takuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Goki Suda, Koji Ogawa, Makoto Chuma, Takashi Meguro, Michio Nakamura, Atsushi Nagasaka, Hiromasa Horimoto, Yoshiya Yamamoto, Naoya Sakamoto.
   A phase I study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma.
   Drugs R&D. 2017;17(3):381-8.
2. Goki Suda, Koji Ogawa, Yoshiya Yamamoto, Masaki Katagiri, Ken Furuya, Kenichi Kumagai, Jun Konno, Megumi Kimura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Jun Ito, Takaaki Izumi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Akihito Tsubota, Noritomo Shimada, Etsuko Iio, Yasuhito Tanaka, Naoya Sakamoto.
   Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
   J. Gastroenterol. 2017;52(10):1122-9.
3. Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Kohei Yuyama, Hideki Nakamura, Qingjie Fu, Osamu Maehara, Goki Suda, Naoya Sakamoto.
   Extracellular vesicles from amnion-derived mesenchymal stem cells ameliorate hepatic inflammation and fibrosis in rats.
   Stem Cells Int. 2018;2018:3212643.
4. Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Hideaki Miyoshi, Naoya Sakamoto.
   Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
   PLoS One. 2018;13(12):e0209615.
5. Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Qingjie Fu, Osamu Maehara, Goki Suda, Naoya Sakamoto.
   Palmitoylethanolamide ameliorates carbon tetrachloride-induced liver fibrosis in rats.
   Front. Pharmacol. 2018;9:709.
6. Masato Nakai, Koji Ogawa, Rei Takeda, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Machiko Umemura, Jun Ito, Takuya Sho, Goki Suda, Kenichi Morikawa, Naoya Sakamoto.
   Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
   Hepatol. Res. 2018;48(3):E311-e9.
7. Goki Suda, Jun Ito, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Munenori Okamoto, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, Takashi Meguro, Masatsugu Ohara, Naoki Kawagishi, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Yoko Tsukuda, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
   Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
   Hepatol. Res. 2018;48(3):E146-e54.
8. Takuya Sho, Goki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Kenichi Kumagai, Minoru Uebayashi, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Manabu Onodera, Takashi Meguro, Megumi Kimura, Jun Ito, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masatsugu Ohara, Yuji Ono, Masato Nakai, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
   Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
   Hepatol. Res. 2018;48(7):529-38.
9. Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto.
   L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis.
   Hepatol. Commun. 2018;2(8):906-18.
10. Ryo Sugiura, Shunsuke Ohnishi, Masatsugu Ohara, Marin Ishikawa, Shuichi Miyamoto, Reizo Onishi, Koji Yamamoto, Kazumichi Kawakubo, Masaki Kuwatani, Naoya Sakamoto.
    Effects of human amnion-derived mesenchymal stem cells and conditioned medium in rats with sclerosing cholangitis.
    Am. J. Transl. Res. 2018;10(7):2102-14.
11. Goki Suda, Masayuki Kurosaki, Jun Itakura, Namiki Izumi, Yoshihito Uchida, Satoshi Mochida, Chitomi Hasebe, Masami Abe, Hiroaki Haga, Yoshiyuki Ueno, Ikuto Masakane, Kazumichi Abe, Atsushi Takahashi, Hiromasa Ohira, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Atsuhiko Kawakami, Kenichi Kumagai, Katsumi Terasita, Masatsugu Ohara, Naoki Kawagishi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J. Gastroenterol. 2019;54(1):78-86.
12. Goki Suda, Chitomi Hasebe, Masami Abe, Masayuki Kurosaki, Jun Itakura, Namiki Izumi, Yoshihito Uchida, Satoshi Mochida, Hiroaki Haga, Yoshiyuki Ueno, Kazumichi Abe, Atsushi Takahashi, Hiromasa Ohira, Yoko Tsukuda, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Jun Inoue, Katsumi Terasita, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J. Gastroenterol. 2019;54(7):641-9.
13. Takaaki Izumi, Takuya Sho, Kenichi Morikawa, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Machiko Umemura, Tomoe Shimazaki, Megumi Kimura, Masato Nakai, Goki Suda, Mitsuteru Natsuizaka, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Kota Ono, Masaru Baba, Ken Furuya, Naoya Sakamoto.
    Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
    Hepatol. Res. 2019;49(10):1207-17.
14. Goki Suda, Megumi Kimura, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto.
    Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
    Hepatol. Res. 2019;49(11):1275-85.
15. Kazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Koji Yamamoto, Taku Shigesawa, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
    Hepatol. Res. 2019;49(11):1294-304.
16. Shinsuke Otagiri, Shunsuke Ohnishi, Masatsugu Ohara, Qingjie Fu, Koji Yamamoto, Keiko Yamamoto, Takehiko Katsurada, Naoya Sakamoto.
    Oleoylethanolamide ameliorates dextran sulfate sodium-induced colitis in rats.
    Front. Pharmacol. 2020;11:1277.
17. Koji Ogawa, Takashi Kobayashi, Jun-Ichi Furukawa, Hisatoshi Hanamatsu, Akihisa Nakamura, Kazuharu Suzuki, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Masato Nakai, Takuya Sho, Goki Suda, Kenichi Morikawa, Masaru Baba, Ken Furuya, Katsumi Terashita, Tomoe Kobayashi, Manabu Onodera, Takahiro Horimoto, Keisuke Shinada, Seiji Tsunematsu, Izumi Tsunematsu, Takashi Meguro, Tomoko Mitsuhashi, Megumi Hato, Kenichi Higashino, Yasuro Shinohara, Naoya Sakamoto.
    Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Sci Rep. 2020;10(1):321.
18. Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto.
    Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
    JGH Open. 2020;4(1):54-60.
19. Masatsugu Ohara, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Tomoe Kobayashi, Minoru Uebayashi, Ryo Takagi, Isao Yokota, Tsuyoshi Shimamura, Naoya Sakamoto.
    Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
    Hepatol. Res. 2020;50(6):715-25.
20. Naoki Kawagishi, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Ren Yamada, Takashi Kitagataya, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Naoya Sakamoto.
    High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
    Hepatol. Res. 2020;50(6):671-81.
21. Takuya Sho, Goki Suda, Koji Ogawa, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Jun Ito, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Katsumi Terasita, Tomofumi Takagi, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto.
    Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
    Hepatol. Res. 2020;50(8):966-77.
22. Masatsugu Ohara,Goki Suda,Megumi Kimura,Osamu Maehara,Tomoe Shimazaki,Taku Shigesawa,Kazuharu Suzuki,Akihisa Nakamura,Naoki Kawagishi,Masato Nakai,Takuya Sho,Mitsuteru Natsuizaka,Kenichi Morikawa,Koji Ogawa,Naoya Sakamoto.
    Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease.
    JCSM Rapid Communications. 2020;3(2): 103-114.
23. Taku Shigesawa, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Ren Yamada, Takashi Kitagataya, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
    JGH Open. 2020;4(5):880-8.
24. Goki Suda, Koji Ogawa, Megumi Kimura, Osamu Maehara, Takashi Kitagataya, Masatsugu Ohara, Yoshimasa Tokuchi, Akinori Kubo, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Naoya Sakamoto.
    Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
    Hepatol. Res. 2020;50(10):1196-200.
25. Takashi Kitagataya, Goki Suda, Kazunori Nagashima, Takehiko Katsurada, Koji Yamamoto, Megumi Kimura, Osamu Maehara, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Yoshito Komatsu, Hiroo Hata, Satoshi Takeuchi, Takashige Abe, Jun Sakakibara-Konishi, Takanori Teshima, Akihiro Homma, Naoya Sakamoto.
    Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    J. Gastroenterol. Hepatol. 2020;35(10):1782-8.
26. Masato Nakai, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Durable response without recurrence to Tolvaptan improves long-term survival.
    J. Gastroenterol. 2020;55(12):1150-61.
27. Taku Shigesawa, Goki Suda, Megumi Kimura, Osamu Maehara, Yoshimasa Tokuchi, Akinori Kubo, Ren Yamada, Ken Furuya, Masaru Baba, Takashi Kitagataya, Kazuharu Suzuki, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    PLoS One. 2021;16(3):e0247728.
28. Kazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Akinobu Nakamura, Hideaki Miyoshi, Megumi Kimura, Osamu Maehara, Ren Yamada, Takashi Kitagataya, Koji Yamamoto, Taku Shigesawa, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto.
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J. Gastroenterol. 2021;56(2):168-80.
29. Taku Shigesawa, Osamu Maehara, Goki Suda, Mitsuteru Natsuizaka, Megumi Kimura, Tomoe Shimazaki, Koji Yamamoto, Ren Yamada, Takashi Kitagataya, Akihisa Nakamura, Kazuharu Suzuki, Masatsugu Ohara, Naoki Kawagishi, Machiko Umemura, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Masaya Sugiyama, Masashi Mizokami, Hiroshi Takeda, Naoya Sakamoto.
    Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Carcinogenesis. 2021;42(1):58-69.
30. Naoki Kawagishi, Goki Suda, Megumi Kimura, Osamu Maehara, Ren Yamada, Yoshimasa Tokuchi, Akinori Kubo, Takashi Kitagataya, Taku Shigesawa, Kazuharu Suzuki, Masatsugu Ohara, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Naoya Sakamoto.
    Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
    Sci Rep. 2021;11(1):9207.
31. Yoshimasa Tokuchi, Goki Suda, Megumi Kimura, Osamu Maehara, Takashi Kitagataya, Masatsugu Ohara, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J. Viral Hepatitis. 2021;28(5):755-63.
32. Sonoe Yoshida, Goki Suda, Masatsugu Ohara, Qingjie Fu, Zijian Yang, Shunichi Hosoda, Megumi Kimura, Kubo Akinori, Yoshimasa Tokuchi, Ren Yamada, Takashi Kitagataya, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Osamu Maehara, Shunsuke Ohnishi, Naoya Sakamoto.
    Frequency and characteristics of overestimated renal function in Japanese patients with chronic liver disease and its relation to sarcopenia.
    Nutrients. 2021;13(7). (equal contribution).
33. Akinori Kubo, Goki Suda, Megumi Kimura, Osamu Maehara, Yoshimasa Tokuchi, Takashi Kitagataya, Masatsugu Ohara, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto.
    Characteristics and lenvatinib treatment response of unresectable hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of EOB-MRI.
    Cancers. 2021;13(14).
34. Yoshimasa Tokuchi, Goki Suda, Megumi Kimura, Osamu Maehara, Takashi Kitagataya, Akinori Kubo, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Shunichi Hosoda, Masatsugu Ohara, Ren Yamada, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto.
    Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
    Sci Rep. 2021;11(1):16616.
35. Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Taku Shigesawa, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Jun Ito, Takuto Miyagishima, Naoya Sakamoto.
    Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
    Hepatol. Res. 2021;51(9):979-89.
36. Kazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, Satoshi Abiko, Kenji Kinoshita, Shuichi Miyamoto, Ryo Sugiura, Megumi Kimura, Osamu Maehara, Ren Yamada, Takashi Kitagataya, Taku Shigesawa, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 2022; 17(1): e0261760.
37. Zijian Yang, Goki Suda, Osamu Maehara, Masatsugu Ohara, Sonoe Yoshida, Shunichi Hosoda, Megumi Kimura, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Ren Yamada, Takashi Kitagataya, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto.
    Changes in serum growth factors during lenvatinib predict the post progressive survival in patients with unresectable hepatocellular carcinoma.
    Cancers. 2022; 14(1):232.
38. Yasue Takeuchi, Masatsugu Ohara, Tatsuya Kanto.
    Nationwide awareness-raising program for viral hepatitis in Japan: the " Shitte kan-en" project.
    Glob Health Med. 2021 Oct 31;3(5):301-307.
39. Junko Tanaka, Akemi Kurisu, Masatsugu Ohara, Serge Ouoba, Masayuki Ohisa, Aya Sugiyama, Michelle L Wang, Lindsey Hiebert, Tatsuya Kanto, Tomoyuki Akita.
    Burden of Chronic Hepatitis B and C Infections in 2015 and Future Trends in Japan.
    Lancet Reg Health West Pac. 2022; 16;22:100428.
40. Takuya Sho, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masaru Baba, Masato Nakai, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    Glecaprevir and pibrentasvir for Japanese patients with human immunodeficiency virus and genotype 3 hepatitis C virus coinfection: A Report of Three Cases.
    Intern. Med. 2019;58(6):797-802. Epub 2018/11/20.
41. Goki Suda, Masato Nakai, Takuya Sho, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masaru Baba, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto.
    The Successful retreatment with glecaprevir and pibrentasvir of Genotype 1 or 2 HCV-infected hemodialysis patients who failed to respond to NS5A and protease inhibitor treatment.
    Intern. Med. 2019;58(7):943-7.
42. 大原 正嗣, 小川 浩司, 長谷川 智子, 新明 康弘, 坂本 直哉, 是永 匡紹
    眼科外来への肝炎医療コーディネーターの配置による肝炎ウイルス陽性者対策の推進
    肝臓　2023年64巻6号289-291
43. Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S, Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
    Hepatol Res. 2022 Jul;52(7):603-613.
44. Kohya R, Suda G, Ohara M, Sasaki T, Yoda T, Sakurai N, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
    Cancers (Basel). 2023 Jun 20;15(12):3257.
45. Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.
    Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
    Liver Cancer. 2022 Oct 31;12(2):156-170.
46. Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, Yoda T, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Komukai S, Ogawa K, Sakamoto N.
    Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
    Hepatol Res. 2023 Jun 18.
47. Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
    Hepatol Res. 2023 Jul;53(7):595-606.
48. Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N.
    Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
    Cancers (Basel). 2023 Jan 18;15(3):593.
49. Hanamatsu H, Makino S, Ohara M, Suda G, Yokota I, Nishihara S, Sakamoto N, Furukawa JI.
    Simultaneous determination of heparan sulfate, chondroitin/dermatan sulfates, and hyaluronan glycosaminoglycan disaccharides by high-performance liquid chromatography using a reverse-phase column with adamantyl groups.
    J Chromatogr A. 2023 Jan 25;1689:463748.
50. Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Hosoda S, Tokuchi Y, Kitagataya T, Ohara M, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
    Viruses. 2023 Jan 7;15(1):181.
51. Nakai M, Morikawa K, Sasaki T, Kohya R, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N.
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 2023 Jul;58(7):656-667.
52. Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M, Mizokami M, Sakamoto N.
    Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
    Hepatol Res. 2022 Jul;52(7):586-596.
53. Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N.
    Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
    Cancers (Basel). 2022 Aug 15;14(16):3938.
54. Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, Yoshida S, Ohara M, Kimura M, Kubo A, Maehara O, Fu Q, Hosoda S, Tokuchi Y, Suzuki K, Nakai M, Sho T, Morikawa K, Natsuizaka M, Ogawa K, Sakai H, Ohnishi S, Baba M, Takehara T, Sakamoto N.
    Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Sci Rep. 2022 Oct 7;12(1):16800.
55. Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N.
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Feb;95(2):e28452.
56. Nakai M, Suda G, Ogawa K, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Ohara M, Sho T, Morikawa K, Sakamoto N.
    Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    PLoS One. 2022 Jul 1;17(7):e0270786.
57. Ohara M, Suda G, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
    Front Nutr. 2023; 6(10)1272728.
58. Yasuura N, Suda G, Ohara M, et al.
    Positivity of high-sensitivity HBsAg test, not previous HBV　infection, indicates poor prognosis in patients with non-HBV-related HCC.
    Aliment Pharmacol Ther. 2024; Sep 4. doi: 10.1111/apt.18229.
59. Sasaki T, Suda G, Ohara M, et al.
    Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
    Hepatol Res. 2023; 53(10);960-967.
60. Yasuura N, Suda G, Ohara M, Sakamoto N.
    Letter: A Positive High-Sensitivity HBsAg Test Was Significantly Associated With Poorer Prognosis in Patients With Non-HBV-Related HCC-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Oct 11.
61. Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, Kobayashi T, Takagi T, Sakamoto N; NORTE STUDY GROUP.
    Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Target Oncol. 2024 Sep;19(5):769-778.
62. Sugiura R, Kuwatani M, Kawakubo K, Kishi K, Yonemura H, Nozawa S, Ohara M, Noji T, Hirano S, Sakamoto N.
    Preoperative risk factors for skeletal muscle mass loss in patients with biliary tract cancer.
    J Hepatobiliary Pancreat Sci. 2024 Aug;31(8):549-558.